ARTEMIS-PH - Study of Ambrisentan in Subjects With Pulmonary Hypertension Associated With Idiopathic Pulmonary Fibrosis
Status:
Terminated
Trial end date:
2011-02-01
Target enrollment:
Participant gender:
Summary
Ambrisentan is an endothelin receptor antagonist used for the treatment of pulmonary
hypertension (PH). Based on research suggesting a role for endothelin-1 in the pathogenesis
of idiopathic pulmonary fibrosis (IPF) and the poor prognosis for patients with IPF who are
also diagnosed with PH, this study was designed to evaluate the effectiveness and safety of
ambrisentan in that patient population.